机译:用Panobinostat / Bortezomib / DexamameSone(FVD)处理血液透析下复发/难治多骨髓瘤的三种情况
Department of Hematology Juntendo University Urayasu Hospital;
Department of Hematology Juntendo University Urayasu Hospital;
Department of Hematology Juntendo University Hospital;
Department of Hematology Juntendo University Hospital;
Department of Hematology Juntendo University Urayasu Hospital;
Department of Hematology Juntendo University Urayasu Hospital;
Department of Pathology Juntendo University Urayasu Hospital;
Department of Pathology Juntendo University Urayasu Hospital;
Department of Clinical Laboratory Juntendo University Urayasu Hospital;
Department of Clinical Laboratory Juntendo University Urayasu Hospital;
Department of Pathology The Institute of Medical Science The University of Tokyo;
Department of Hematology Juntendo University Hospital;
Department of Hematology Juntendo University Urayasu Hospital;
Relapsed/refractory multiple myeloma; Renal failure; Hemodialysis; Panobinostat/bortezomib/dexamethasone (FVD) therapy;
机译:用Panobinostat / Bortezomib / DexamameSone(FVD)处理血液透析下复发/难治多骨髓瘤的三种情况
机译:Panobinostat加硼替佐米和地塞米松与安慰剂加硼替佐米和地塞米松在复发或复发且难治性多发性骨髓瘤患者中的一项多中心,随机,双盲3期试验
机译:潘诺比司他加硼替佐米和地塞米松在治疗复发或难治性多发性骨髓瘤中的作用:欧洲观点
机译:用髓质族,多柔比星和地塞米松治疗引起的蛋白质组学改变
机译:Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物,最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
机译:Panobinostat联合硼替佐米和地塞米松在治疗复发或难治性多发性骨髓瘤中的作用:欧洲观点
机译:Panobinostat联合硼替佐米和地塞米松在治疗复发或难治性多发性骨髓瘤中的作用:欧洲观点